RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors.

Cíntia Regina Niederauer Ramos,Renato José Silva Oliveira,Marcela Nunes Rosa, Ariane Stéfani Pereira, Renata Barbosa Vahia de Abreu,Andre van Helvoort Lengert,Rui Manuel Reis,Viviane Aline Oliveira Silva,Edenir Inêz Palmero,Matias Eliseo Melendez

Current cancer drug targets（2023）

引用 0|浏览2

暂无评分

摘要

T47D RAD50 deficient cells treated with PARP inhibitors alone or in combination with carboplatin showed cell cycle arrest in the G2/M phase, leading to death by apoptosis. Thus, RAD50 deficiency may be a good biomarker for predicting PARPi response.

查看译文

关键词

Breast cancer,DNA repair,Homologous Recombination,PARP inhibitors,Synthetic lethality,Target therapy.

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要